As BMPR2 mutations are the most established and prevalent genetic cause of PAH, many different approaches have been explored to target BMP signaling in treating PAH, mostly by restoring cell surface BMPR‐II expression and/or enhancing BMP signaling. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.